ADT-007, a first-in-class pan-RAS inhibitor, addresses complex RAS mutational landscape of human cancers
Cancer Researchers from ADT Pharmaceuticals and affiliated organizations have published preclinical data for the pan-RAS inhibitor ADT-007, being developed as an anticancer agent. BioWorld Science Cancer